Summit Therapeutics Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Summit Therapeutics Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. NEWS RELEASE Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 2026-05-30 Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70. 0%; Responses Consistent Across Ivonescimab Dose Levels Combined with Chemotherapy Ac…